Assisted Fluid Management (AFM) System and Postoperative Outcome After High-risk Abdominal Surgery

Last updated: June 24, 2025
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

AFM

Routine care

Clinical Study ID

NCT06011187
APHP 220817
  • Ages > 18
  • All Genders

Study Summary

Goal directed fluid therapy (GDFT) or "Personalized fluid therapy" may benefit high-risk surgical patients but these strategies are infrequently implemented. It has also been shown that without any goal or protocol for fluid resuscitation, large inter- and intra-provider variability exist that have been correlated with poor patient outcomes.

Recently, an "Assisted Fluid Management" (AFM) system has been developed to help ease some of the work associated with GDFT protocol implementation. The AFM system may help increase GDFT protocol adherence while leaving direction and guidance in the hands of the care providers. This artificial intelligence-based system can suggest administration of fluid boluses, analyse the hemodynamic effects of the bolus, and continually re-assess the patient for further fluid requirements.

To date, there are no large outcome study using this AFM system. The primary objective of this trial is thus to evaluate the impact of this AFM system to guide fluid bolus administration on a composite of major postoperative complications in high-risk patients undergoing high-risk abdominal surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Any adult patient (aged 18 years or older) admitted to the operating room for anelective high-risk abdominal surgery (both open and laparoscopically assisted).

  • Patients must fulfill at least one of the following high-risk criteria:

  • American Society of Anesthesiologists physical status > 2

  • classification exercise tolerance < 4 metabolic equivalents as defined by theguidelines of the American College of Cardiology/ American Heart Association

  • renal impairment (serum creatinine ≥1.3mg/dL or >115 mmol/l or estimated glomerularfiltration rate < 90 mL/min/1.73 m2 within the last 6 months) or renal replacementtherapy

  • coronary artery disease (any stage)

  • chronic heart failure (New York Heart Association Functional Classifcation ≥ II)

  • valvular heart disease (moderate or severe);

  • history of stroke

  • peripheral arterial occlusive disease (any stage)

  • chronic obstructive pulmonary disease (any stage) or pulmonary fibrosis (any stage)

  • diabetes mellitus requiring oral hypoglycemic agent or insulin; immunodeficiency dueto a disease (e.g., HIV, leukemia, multiple myeloma, solid organ cancer) or therapy (e.g., immunosuppressants, chemotherapy, radiation, steroids)

  • liver cirrhosis (any Child-Pugh class)

-- body mass index ≥30 kg/m2

  • current smoking or 15 pack-year history of smoking

  • All participants must receive clear study information and give signed informedconsent

Exclusion

Exclusion Criteria:

  • Patients with preoperative cardiac arrhythmias (atrial fibrillation) as themonitoring devices are not accurate under cardiac arrhythmias.

  • No affiliation with the French health care system

  • Patients participating in another randomized controlled trial with the same clinicalendpoint, or interventions possibly compromising the primary outcome.

  • Pregnant patients

  • Patient on AME (state medical aid) (unless exemption from affiliation)

  • Patients guardianship/legal protection/curatorship

Study Design

Total Participants: 2000
Treatment Group(s): 2
Primary Treatment: AFM
Phase:
Study Start date:
February 01, 2024
Estimated Completion Date:
December 30, 2026

Study Description

Many trials have indicated that goal-directed fluid therapy (GDFT) strategies or more recently "personalized fluid therapy" may benefit high-risk surgical patients but these strategies are infrequently implemented. It has also been shown that without any goal or protocol for fluid resuscitation, large inter- and intra-provider variability exist that have been correlated with poor patient outcomes. Even under ideal study conditions, strict adherence to GDFT protocols is hampered by the workload and concentration required for consistent implementation. Hemodynamic monitors and protocols alone do not enable optimal fluid titration to be provided consistently to all patients - there must also be appropriate and timely interpretation and intervention.

To address this problem of consistency and protocol adherence, a decision support system, "Assisted Fluid Management" (AFM), has been developed to help ease some of the work associated with GDFT protocol implementation. The AFM system (released on the European market in March 2017) may help increase GDFT protocol adherence while leaving direction and guidance in the hands of the care providers. This artificial intelligence-based system can suggest administration of fluid boluses, analyse the hemodynamic effects of the bolus, and continually re-assess the patient for further fluid requirements.

This system was recently implemented in a before-and-after study in a Belgian academic hospital, where the authors reported that the implementation of this AFM software system allowed a better adherence to the GDFT algorithm. However, as this was a pilot study with a small number of patients, the study was not powered to demonstrate a beneficial effect on the incidence of postoperative complications. More recently, a group from the Cleveland Clinic demonstrated that using AFM system resulted in more boluses being effective when compared to the administration of boluses without AFM support.

There are no randomized controlled studies to date comparing this AFM system to standard of care on patient outcome. We therefore aim to conduct a multicenter stepped-wedge, cluster-randomized trial involving patients undergoing high risk abdominal surgery to compare a GDFT strategy guided by the AFM system with usual care.

A stepped wedge, cluster-randomized trial approach was chosen in which clusters will be randomized to commence the intervention at different times following an initial control period in which outcomes will be measured for usual care.

So, each center (cluster) began in the control phase and transitioned to the intervention phase at a randomly assigned time (wedge). The order in which each center will move from control to intervention phase will be randomly allocated by a computer algorithm performed by the study statistician.

We selected cluster randomization rather than randomization of individual patients because the control group could be very different among centers (from GDFT strategy using a flow monitoring to GDFT with a written protocol to no clear strategy (use of an arterial line only without any advanced monitoring). Interestingly, this approach also decreases the Hawthorne effect which has been shown to decrease the incidence rate of the primary outcome in recent randomized trials because clinicians know that their patients are included in a research protocol.

Connect with a study center

  • UZ Brussels

    Brussel,
    Belgium

    Active - Recruiting

  • CHUM Montreal

    Montréal, Montreal
    Canada

    Active - Recruiting

  • Centre chirurgical Marie Lannelongue

    Le Plessis-Robinson, Haut de Seine
    France

    Active - Recruiting

  • BICETRE

    Le Kremlin-Bicêtre, Paris
    France

    Active - Recruiting

  • CHU Clermont-Ferrand

    Clermont-Ferrand,
    France

    Site Not Available

  • Chu Dijon

    Dijon,
    France

    Active - Recruiting

  • Chu Grenoble Alpes

    Grenoble,
    France

    Active - Recruiting

  • ALEXANDRE JOOSTEN, MD PhD

    Le Kremlin-Bicêtre, 94200
    France

    Active - Recruiting

  • Chu Lille

    Lille,
    France

    Active - Recruiting

  • Centre hospitalier universitaire de NANCY

    Nancy,
    France

    Active - Recruiting

  • BEAUJON

    Paris,
    France

    Active - Recruiting

  • HEGP

    Paris,
    France

    Active - Recruiting

  • Insititut Mutualiste Montsouris

    Paris,
    France

    Active - Recruiting

  • La Pitie Salpetriere

    Paris,
    France

    Active - Recruiting

  • Chu Toulouse

    Toulouse,
    France

    Active - Recruiting

  • University Medical Center Hamburg-Eppendorf

    Hamburg,
    Germany

    Site Not Available

  • University of California IRVINE

    Irvine, California 92868
    United States

    Active - Recruiting

  • University of California Los Angeles (UCLA)

    Los Angeles, California 90095
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.